ArticleOncoimmunology
BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Repurposing rosmarinic acid as an anti-colorectal cancer agent through bolstering T cell anti-tumor immunity by enhancing activation of MEK1-mediated TCR signaling.Cancer immunology, immunotherapy : CII · 2026Article
- Superior efficacy of vemurafenib combined with iodine-131 for lymph node metastatic BRAF-mutant thyroid cancer: a long-term survival analysis.American journal of translational research · 2026Article
- PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods.World journal of methodology · 2024Review
- Comprehensive single-cell RNA-seq analysis using deep interpretable generative modeling guided by biological hierarchy knowledge.Briefings in bioinformatics · 2024Article
- Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center's decade of experience.Frontiers in oncology · 2024Article
- Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.Journal of experimental & clinical cancer research : CR · 2023Review
- Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.Nature communications · 2022Article
- Biomimetic nanoparticles for tumor immunotherapy.Frontiers in bioengineering and biotechnology · 2022Review
- Computational recognition of LncRNA signatures in tumor-associated neutrophils could have implications for immunotherapy and prognostic outcome of non-small cell lung cancer.Frontiers in genetics · 2022Article
- IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses.International journal of molecular sciences · 2021Article
- BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes.Cancer immunology, immunotherapy : CII · 2021Article
- Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients.Clinical and translational medicine · 2021Article
- Article
- Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy.International journal of nanomedicine · 2021Review
- Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy.International journal of molecular sciences · 2020Article
- Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth.Cell reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) such as the anti-PD-1 antibody Nivolumab, achieve remarkable clinical efficacy in patients with late stage cancers. However, only a small subset of patients benefit from this therapy. Numerous clinical trials are underway testing whether combining ICIs with other anti-cancer therapies can increase this response rate. For example, anti-PD-1/PD-L1 therapy combined with MAP kinase inhibition using BRAF inhibitors (BRAFi) and/or MEK inhibitors (MEKi) are in development for treatment of late stage melanomas. However, the benefits and underlying mechanisms of these combinatorial therapies remain unclear. In the current study, we assess the effects of MAPK inhibition on Nivolumab-induced T cell responses. Using an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.